Decoy Therapeutics Bolsters IP Portfolio with Seven Patent Families
Event summary
- Decoy Therapeutics now holds seven patent families and 19 pending applications across seven jurisdictions.
- Portfolio includes one granted U.S. patent (No. 12,226,474) covering antiviral peptide conjugates with D-amino acids.
- Newest filing protects the IMP³ACT™ design platform's methods for creating engineered peptides.
- Pending applications span compositions, manufacturing methods, formulations, and platform technology.
The big picture
Decoy Therapeutics' expanding IP portfolio reflects its shift from protecting initial conjugates to safeguarding its AI-driven design platform. This strategic move aligns with the biotech industry's trend toward flexible, multi-target antivirals amid growing demand for pandemic preparedness solutions. The company's ability to secure broad patent protection will be critical in attracting partners and investors as it advances candidates into clinical development.
What we're watching
- Patent Grant Risk
- Whether all pending applications will be granted, given the broad scope of claims.
- Platform Scalability
- The pace at which IMP³ACT™ can design and synthesize new antiviral candidates.
- Competitive Positioning
- How Decoy's IP strategy will differentiate it from traditional antiviral developers.
Related topics